酒石酸美托洛尔片用于慢性阻塞性肺疾病合并慢性心力衰竭患者的临床观察

Clinical observation of the effects of metoprolol tartrate tablets on patients with chronic obstructive pulmonary disease complicated with chronic heart failure

目的评价酒石酸美托洛尔片应用于Ⅱ～Ⅲ级慢性阻塞性肺疾病(COPD)合并慢性心功能不全(CHF)患者的疗效和安全性。方法 71例COPD合并CHF的患者随机分入美托洛尔组和对照组。对照组常规治疗,美托洛尔组在常规治疗基础上加用酒石酸美托洛尔,观察2组患者治疗前和治疗后1,3,6个月时的肺功能变化,生活质量评估(SGRQ)变化,6 min步行距离(6 MWT)和再次入院率。结果治疗前后2组间的肺功能差异无统计学意义(P>0.05),美托洛尔组6个月时的SGRQ和6 MWT改善情况和再次入院率均好于对照组,差异有统计学意义(P<0.05)。结论酒石酸美托洛尔片应用于Ⅱ～Ⅲ度COPD合并CHF患者具有良好的安全性和耐受性,并改善生活质量,减少再次住院率。

Objective To evaluate the safety and effect of the metoprolol tartrate tablets on the patients with chronic obstructive pulmonary disease complicated with chronic heart failure. Methods Seventy one patients were randomly divided into metoprolol group and control group. Both groups recieved routine treatment while metoprolol group added metoprolo]. The lung function test , the St George＇ s respiratory question- naire scorc（SGRQ） and 6 minitue walk test （6MWT） were performed and compared at baseline and at 1,3 and 6 months after drug administration in two groups. At the same time, the rate of recurrent hospitalization were obsmwed in two groups. Results There was no significant difference in lung function between two groups. The SGRQ and 6MWT after half a year in metoprolol group were significantly better than the metoprolol group. The rate of recurrent hospitalization in metoprolol group was significantly lower than the metoprolol group. Conclusion The metoprolol tartrate tablets is effective and safe for improving the exercising endurance and decreaeing the rate of recurrent hospitalization in patients with chronic obstructive pulmonary disease complicated with chronic heart failure.